CLNN · Clene Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern. To mitigate our funding needs, we plan to raise additional funding, including exploring equity financing and offerings, debt financing, licensing or collaboration arrangements with third parties, as well as utilizing our existing at-the-market facility and potential proceeds from the exercise of outstanding warrants and stock options. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of our plans will result in the necessary funding to continue current operations. During the three and six months ended June 30, 2026, we raised $7.0 million and $13.0 million, respectively, of gross proceeds from registered direct offerings of equity securities (see Note 13 to the condensed consolidated financial statements). While we have implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts, reducing employee compensation, and eliminating certain staff positions, we have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements contained in this report are issued.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $197K | $200K | $342K | $654K | $473K | $723K | $206K | — | |
| — | — | — | — | -$3.3M | -$870K | — | — | |
| $59K | $43K | $70K | $121K | $26K | $289K | — | — | |
| $138K | $157K | $272K | $533K | $447K | $434K | — | — | |
| — | 78.5% | 79.53% | 81.5% | 94.5% | 60.03% | — | — | |
| $12.82M | $14.01M | $20.06M | $26.66M | $31.92M | $28.42M | $15.2M | $9.56M | |
| $7.87M | $9.23M | $13.31M | $14.42M | $16.94M | $22M | $5.15M | $6.77M | |
| $51.23M | — | — | — | — | $50.7M | $20.42M | $16.33M | |
| $20.75M | $23.28M | $33.44M | $41.19M | $48.88M | $50.7M | — | — | |
| -$20.55M | -$23.08M | -$33.09M | -$40.54M | -$48.41M | -$49.98M | -$20.21M | -$16.33M | |
| — | -11541.5% | -9676.32% | -6198.78% | -10234.46% | -6912.59% | -9812.62% | — | |
| $2.88M | $2.68M | $4.06M | $4.56M | $3.3M | $870K | $950K | $88K | |
| $182K | $223K | $865K | $1.39M | $225K | — | — | — | |
| -$18.97M | -$3.09M | -$6.31M | -$8.96M | $18.49M | $39.81M | $1.34M | $177K | |
| -$39.52M | -$26.17M | -$39.4M | -$49.5M | -$29.92M | -$10.17M | -$18.87M | -$16.16M | |
| $0 | $0 | $0 | $0 | $0 | -$428K | $406K | — | |
| -$39.52M | -$26.17M | -$39.4M | -$49.5M | -$29.92M | -$9.74M | -$19.28M | -$16.16M | |
| — | -13086.5% | -11520.47% | -7569.42% | -6325.16% | -1347.16% | -9357.77% | — | |
| -$39.46M | -$26.07M | -$39.53M | -$49.51M | -$29.95M | -$9.83M | -$18.99M | -$16.16M | |
| USD/shares | -$3.55 | -$2.65 | -$5.67 | -$9.43 | -$9.20 | -$3.20 | — | — |
| shares | — | 9.86M | 6.95M | 5.25M | 3.26M | 3.08M | 875.2K | 867.88K |
| shares | — | — | — | — | — | 3.08M | 875.2K | 867.88K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Long-term debt, including current maturities | 2026-06-30 | USD 17,604,000 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Operating lease liabilities | 2026-06-30 | USD 3,620,000 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 28 similar-size Packaged Foods companies (of 73 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2022 | FY2021 |
|---|---|---|
| Supplements Segment | $473,000 | $723,000 |
| Drugs Segment | $0 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $119,000 | $237,000 | $498,000 | $329,000 | $570,000 | $176,000 |
| Royalty | $81,000 | $105,000 | $156,000 | $144,000 | $153,000 | $30,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2022 | FY2021 |
|---|---|---|
| Supplements Segment | $360,000 | $205,000 |
| Drugs Segment | -$48,769,000 | -$50,183,000 |
Operating Margin by Segment (%)
| Component | FY2022 | FY2021 |
|---|---|---|
| Supplements Segment | 76.1% | 28.4% |